Analysts have been eager to weigh in on the Healthcare sector with new ratings on TrovaGene (TROV) and Spark Therapeutics (ONCE).
TrovaGene (TROV)
In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on TrovaGene, with a price target of $8. The company’s shares opened today at $3.15, close to its 52-week low of $2.54.
McCarthy observed:
“Trovagene reported FY18 earnings with net loss of ($16.5M), and ended the year with $11.5M in cash and cash equivalents. Fundamentals remain intact, onvansertib continues to advance in the clinic; AML, prostate cancer and coming next, colorectal cancer.”
According to TipRanks.com, McCarthy is ranked 0 out of 5 stars with an average return of -6.0% and a 31.2% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Aridis Pharmaceuticals Inc, Adial Pharmaceuticals Inc, and Actinium Pharmaceuticals.
TrovaGene has an analyst consensus of Moderate Buy, with a price target consensus of $6.50, which is a 106.3% upside from current levels. In a report issued on February 20, Noble Financial also maintained a Buy rating on the stock with a $5 price target.
See today’s analyst top recommended stocks >>
Spark Therapeutics (ONCE)
In a report released today, Raju Prasad from William Blair downgraded Spark Therapeutics to Hold. The company’s shares opened today at $113.70, close to its 52-week high of $114.20.
According to TipRanks.com, Prasad is a 5-star analyst with an average return of 18.6% and a 57.7% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Logicbio Therapeutics Inc, and Audentes Therapeutics.
Spark Therapeutics has an analyst consensus of Hold, with a price target consensus of $98.12, a -13.7% downside from current levels. In a report issued on February 25, Mizuho Securities also downgraded the stock to Hold with a $114.50 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ONCE:
